Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rfviii-Fc
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study
Details : Rfviii-Fc is a Protein-drug Conjugate drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein-drug Conjugate
Upfront Cash : Inapplicable
November 18, 2023
Lead Product(s) : Rfviii-Fc
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eptacog Alfa is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 10, 2021
Lead Product(s) : Eptacog Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable